Cabozantinib and prostate cancer: Inhibiting seed and disrupting soil?

Clinical Cancer Research

Volumn 20, Issue 3, 2014, Pages 525-527

  Lee, Richard J ^a   Smith, Matthew R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL PROLIFERATION; HUMANS; MALE; OSTEOBLASTS; PROSTATIC NEOPLASMS; PYRIDINES;

EID: 84893435624     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2636     Document Type: Article

References (5)

1. Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff KM, Aftab DT, et al. Cabozantinib inhibits prostate cancer growth and prevents tumorinduced bone lesions. Clin Cancer Res 2014;20:617-30.
2. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-9.
3. Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J 2013;19:90-8.
4. Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-46.
5. Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013;19:3088-94.